{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:36Z","timestamp":1790806836402,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The phase 3, open-label, randomised, crossover MG0020 study investigated rozanolixizumab self-administration, efficacy, and safety in patients with generalised myasthenia gravis (gMG) using infusion pump and manual push methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with gMG received once-weekly rozanolixizumab for 18\u00a0weeks, comprising a 6-week Training Period and two 6-week Self-Administration Periods where patients were randomised 1:1 to Sequence 1 (infusion pump then manual push) or Sequence 2 (manual push then infusion pump). The primary endpoint was successful rozanolixizumab self-administration (choosing correct infusion site, administering subcutaneously, delivering intended dose), evaluated by a healthcare professional (HCP) at weeks 12 and 18. Secondary endpoints included treatment-emergent adverse events (TEAEs). Additional endpoints included change from baseline in total immunoglobulin G (IgG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and patients\u2019 administration method preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-two patients received treatment; 55 were randomised (Sequence 1:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928; Sequence 2:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927). The self-administration success rate was 100% with both methods. Decreases from baseline in IgG and MG-ADL score were maintained during self-administration with both methods. TEAEs occurred in 47\/62 (75.8%) patients; most events (161\/165 [97.6%]) were mild or moderate. Incidence was comparable for both methods. Most patients (35\/55 [63.6%]) preferred self-administration to HCP administration (5\/55 [9.1%]); more preferred manual push (25\/55 [45.5%]) to infusion pump (17\/55 [30.9%]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All patients successfully self-administered rozanolixizumab; more patients preferred manual push. Efficacy and safety were consistent with the known HCP-administered profile. These results support rozanolixizumab self-administration and manual push administration in patients with gMG.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : NCT05681715 (registered 4 January 2023).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-13420-6","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:36:52Z","timestamp":1760186212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct05681715","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Berkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Dru\u017cd\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana K.","family":"Gandhi Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabeen K.","family":"Mahuwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zsch\u00fcntzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Boehnlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Kerbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Lavrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"13420_CR1","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/847393","volume":"2011","author":"NE Gilhus","year":"2011","unstructured":"Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA (2011) Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011:847393. https:\/\/doi.org\/10.4061\/2011\/847393","journal-title":"Autoimmune Dis"},{"issue":"1","key":"13420_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"13420_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X (2023) New and emerging treatments for myasthenia gravis. BMJ Med 2(1):e000241. https:\/\/doi.org\/10.1136\/bmjmed-2022-000241","journal-title":"BMJ Med"},{"key":"13420_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jocn.2019.08.113","volume":"72","author":"KJB Adiao","year":"2020","unstructured":"Adiao KJB, Espiritu AI, Roque VLA, Reyes JPBT (2020) Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: a systematic review. J Clin Neurosci 72:316\u2013321. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.113","journal-title":"J Clin Neurosci"},{"issue":"5","key":"13420_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J (2018) Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 32(5):425\u2013440. https:\/\/doi.org\/10.1007\/s40259-018-0295-0","journal-title":"BioDrugs"},{"issue":"3S","key":"13420_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y et al (2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 139(3S):S1\u2013S46. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"13420_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2217\/imt-2021-0313","volume":"14","author":"RH Kobayashi","year":"2022","unstructured":"Kobayashi RH, Litzman J, Rizvi S, Kreuwel H, Hoeller S, Gupta S (2022) Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Immunotherapy 14(4):259\u2013270. https:\/\/doi.org\/10.2217\/imt-2021-0313","journal-title":"Immunotherapy"},{"issue":"1","key":"13420_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/1744666X.2020.1858803","volume":"17","author":"R Caporali","year":"2021","unstructured":"Caporali R, Allanore Y, Alten R, Combe B, Durez P, Iannone F, Nurmohamed MT et al (2021) Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Rev Clin Immunol 17(1):85\u201399. https:\/\/doi.org\/10.1080\/1744666X.2020.1858803","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"13420_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","volume":"107","author":"MR Turner","year":"2018","unstructured":"Turner MR, Balu-Iyer SV (2018) Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. J Pharm Sci 107(5):1247\u20131260. https:\/\/doi.org\/10.1016\/j.xphs.2018.01.007","journal-title":"J Pharm Sci"},{"issue":"2","key":"13420_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000809","volume":"4","author":"K Lauper","year":"2018","unstructured":"Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordstr\u00f6m D, Pavelka K et al (2018) Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open 4(2):e000809. https:\/\/doi.org\/10.1136\/rmdopen-2018-000809","journal-title":"RMD Open"},{"issue":"9","key":"13420_CR11","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0171","volume":"13","author":"V Bril","year":"2024","unstructured":"Bril V, Lampe J, Cooper N, Kiessling P, Gardulf A (2024) Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. J Comp Eff Res 13(9):e230171. https:\/\/doi.org\/10.57264\/cer-2023-0171","journal-title":"J Comp Eff Res"},{"key":"13420_CR12","unstructured":"Hizentra EU SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hizentra-epar-product-information_en.pdf. Accessed July 2025."},{"key":"13420_CR13","unstructured":"HyQvia EU SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf. Accessed July 2025."},{"issue":"11","key":"13420_CR14","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1007\/s10072-024-07640-3","volume":"45","author":"A Ramzi","year":"2024","unstructured":"Ramzi A, Maya S, Balousha N, Sabet H, Samir A, Roshdy MR, Aljarrah G et al (2024) Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): a comprehensive systematic review of clinical studies and meta-analysis. Neurol Sci 45(11):5213\u20135230. https:\/\/doi.org\/10.1007\/s10072-024-07640-3","journal-title":"Neurol Sci"},{"key":"13420_CR15","unstructured":"Zilbrysq EU SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf. Accessed July 2025."},{"key":"13420_CR16","unstructured":"Vyvgart EU SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf. Accessed July 2025."},{"key":"13420_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/ppa.s303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA (2021) Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 15:811\u2013834. https:\/\/doi.org\/10.2147\/ppa.s303279","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"13420_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol 22(5):395\u2013406. https:\/\/doi.org\/10.1016\/s1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"issue":"2","key":"13420_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1017\/cjn.2021.56","volume":"49","author":"D Menon","year":"2022","unstructured":"Menon D, Sarpong E, Bril V (2022) Practical aspects of transitioning from intravenous to subcutaneous immunoglobulin therapy in neuromuscular disorders. Can J Neurol Sci 49(2):161\u2013167. https:\/\/doi.org\/10.1017\/cjn.2021.56","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"13420_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10875-018-0507-x","volume":"38","author":"B Bienvenu","year":"2018","unstructured":"Bienvenu B, Cozon G, Mataix Y, Lachaud D, Alix A, Hoarau C, Antier D et al (2018) Rapid push vs pump-infused subcutaneous immunoglobulin treatment: a randomized crossover study of quality of life in primary immunodeficiency patients. J Clin Immunol 38(4):503\u2013512. https:\/\/doi.org\/10.1007\/s10875-018-0507-x","journal-title":"J Clin Immunol"},{"issue":"1","key":"13420_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00876-6","volume":"41","author":"J Cowan","year":"2021","unstructured":"Cowan J, Bonagura VR, Lugar PL, Maglione PJ, Patel NC, Vinh DC, Hofmann JH et al (2021) Safety and tolerability of manual push administration of subcutaneous IgPro20 at high infusion rates in patients with primary immunodeficiency: findings from the manual push administration cohort of the HILO study. J Clin Immunol 41(1):66\u201375. https:\/\/doi.org\/10.1007\/s10875-020-00876-6","journal-title":"J Clin Immunol"},{"issue":"2","key":"13420_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","volume":"30","author":"R Shapiro","year":"2010","unstructured":"Shapiro R (2010) Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 30(2):301\u2013307. https:\/\/doi.org\/10.1007\/s10875-009-9352-2","journal-title":"J Clin Immunol"},{"issue":"7","key":"13420_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 10(7):1111\u20131130. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"issue":"5","key":"13420_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"2","key":"13420_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/22143602241308181","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Dru\u017cd\u017c A, Grosskreutz J, Mantegazza R, Sacconi S, Utsugisawa K, Vu T et al (2025) Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: results from the phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis 12(2):231\u2013243. https:\/\/doi.org\/10.1177\/22143602241308181","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"13420_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/22143602241305511","volume":"12","author":"V Bril","year":"2025","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K et al (2025) Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis 12(2):218\u2013230. https:\/\/doi.org\/10.1177\/22143602241305511","journal-title":"J Neuromuscul Dis"},{"key":"13420_CR27","unstructured":"Rystiggo EU SmPC (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rystiggo-epar-product-information_en.pdf. Accessed July 2025"},{"key":"13420_CR28","unstructured":"Rystiggo US PI (2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf. Accessed July 2025"},{"key":"13420_CR29","unstructured":"Rystiggo Japan PI (2025) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_6399432A1028_1_05. Accessed July 2025"},{"issue":"6","key":"13420_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C (2024) Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol 31(6):e16180. https:\/\/doi.org\/10.1111\/ene.16180","journal-title":"Eur J Neurol"},{"key":"13420_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-7525-9-2","volume":"9","author":"D Keininger","year":"2011","unstructured":"Keininger D, Coteur G (2011) Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes 9:2. https:\/\/doi.org\/10.1186\/1477-7525-9-2","journal-title":"Health Qual Life Outcomes"},{"key":"13420_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106240","volume":"198","author":"D Cocito","year":"2020","unstructured":"Cocito D, Peci E, Rigaldo S, Canavese C, Migliaretti G, Cossa FM (2020) Manual push technique, an alternative route of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyradiculoneuropathy: a proof-of-concept study. Clin Neurol Neurosurg 198:106240. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106240","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"13420_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00415-025-12958-9","volume":"272","author":"V Bril","year":"2025","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S et al (2025) Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol 272(4):275. https:\/\/doi.org\/10.1007\/s00415-025-12958-9","journal-title":"J Neurol"},{"issue":"12","key":"13420_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70230","volume":"7","author":"G Geonnotti","year":"2024","unstructured":"Geonnotti G, Pesa J, Peters W, Taylor M, Choudhry Z, Falope O, Price M et al (2024) Design of and early insights from a generalized myasthenia gravis Patient Engagement Research Council. Health Sci Rep 7(12):e70230. https:\/\/doi.org\/10.1002\/hsr2.70230","journal-title":"Health Sci Rep"},{"issue":"5","key":"13420_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(5):1016\u20131027. https:\/\/doi.org\/10.1002\/art.40049","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"13420_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP et al (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17(1):35\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(17)30378-2","journal-title":"Lancet Neurol"},{"issue":"6","key":"13420_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","volume":"31","author":"M Borte","year":"2011","unstructured":"Borte M, Quinti I, Soresina A, Fern\u00e1ndez-Cruz E, Ritchie B, Schmidt DS, McCusker C (2011) Efficacy and safety of subcutaneous vivaglobin\u00ae replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol 31(6):952\u2013961. https:\/\/doi.org\/10.1007\/s10875-011-9588-5","journal-title":"J Clin Immunol"},{"issue":"4","key":"13420_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/mus.28038","volume":"69","author":"KG Gwathmey","year":"2024","unstructured":"Gwathmey KG, Ding H, Hehir M, Silvestri N (2024) How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis? Muscle Nerve 69(4):389\u2013396. https:\/\/doi.org\/10.1002\/mus.28038","journal-title":"Muscle Nerve"},{"issue":"1","key":"13420_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C (2023) Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther 12(1):107\u2013128. https:\/\/doi.org\/10.1007\/s40120-022-00408-x","journal-title":"Neurol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13420-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:03:59Z","timestamp":1764792239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13420-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13420"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13420-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Formatting changes in the table 2 i.e.  indent \u201cHeadache\u201d word to the same extent as 'COVID-19' have been done.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V. Bril is a consultant for Akcea, Alexion Pharmaceuticals, Alnylam, argenx, CSL, Grifols, Immunovant, Ionis, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson), Novo Nordisk, Octapharma, Pfizer, Powell Mansfield, Roche, Sanofi, Takeda Pharmaceuticals and UCB. She has received research support from Akcea, Alexion Pharmaceuticals, argenx, CSL, Grifols, Immunovant, Ionis, Momenta (now Johnson & Johnson), Octapharma, Takeda Pharmaceuticals, UCB and Viela Bio (now Amgen). C. Antozzi has received funding for congress and Institutional Review Board participation from Alexion Pharmaceuticals, argenx, Biogen, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson) and UCB. T. Berkowicz has nothing to disclose. A. Dru\u017cd\u017c has nothing to disclose. R.K. Gandhi Mehta has received research funding from Akcea Pharmaceuticals (now AstraZeneca), EMD Serono, Novartis and UCB. She has served on advisory boards for Amgen and UCB and has received speaker honoraria from UCB. Z.K. Mahuwala has received compensation for advisory board participation from Alexion Pharmaceuticals and Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine) and has served as a panellist for Academic CME. She has received research funding for clinical trials paid to the University of Kentucky from Alexion Pharmaceuticals, argenx, Immunovant, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), RemeGen Biosciences and UCB. J. Zsch\u00fcntzsch has been awarded research grants from the German Innovationfond, German Society for Muscle Disease (DGM), and the Innovative Medicines Initiative 2 Joint Undertaking (IMI JU) of the European Commission (Grant Number: 101034427-2). She has received speaker honoraria or travel grants from Alexion, argenx, Kedrion, Roche and Sanofi. She serves on scientific or educational advisory boards for Alexion, Amicus, argenx, iThera, Kedrion, Sanofi, and UCB. She has received research support from argenx and UCB. She is a member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and a member of the medical advisory boards of the DGM and the German Myasthenia Gravis Society. M. Boehnlein is an employee and shareholder of UCB. V. Kerbusch is a paid Consultant for UCB. A. Lavrov is an employee and shareholder of UCB. M. Morris is an employee and shareholder of UCB. P. Singh is an employee and shareholder of UCB, and is a previous employee and shareholder of GSK. M.I. Leite is funded by the NHS (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, UK. She has been awarded research grants from UK associations for patients with myasthenia and with muscular disorders (Myaware and Muscular Dystrophy UK, respectively) and the University of Oxford. She has received speaker honoraria or travel grants from Biogen, the Guthy-Jackson Charitable Foundation, Novartis and UCB. She serves on scientific or educational advisory boards for argenx, Horizon Therapeutics (now Amgen) and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study protocol, amendments, and study participant informed consent were approved by a national, regional or independent ethics committee or institutional review board. All patients provided the written informed consent. This study was conducted in accordance with local regulations, International Conference on Harmonization Good Clinical Practice requirements, and the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"686"}}